OUTCOME AFTER FIRST RELAPSE IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - A POPULATION-BASED STUDY OF 315 PATIENTS FROM THE NORDIC-SOCIETY-OF-PEDIATRIC-HEMATOLOGY-AND-ONCOLOGY (NOPHO)

被引:44
|
作者
SCHROEDER, H
GARWICZ, S
KRISTINSSON, J
SIIMES, MA
WESENBERG, F
GUSTAFSSON, G
机构
[1] Departments of Pediatrics, University Hospital of Aarhus, Aarhus
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 1995年 / 25卷 / 05期
关键词
ALL; CHILDREN; OUTCOME AFTER RELAPSE; GENDER;
D O I
10.1002/mpo.2950250503
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study reports the outcome after relapse of acute lymphoblastic leukemia (ALL) in a population-based study of 809 children over 1 year of age diagnosed July 1981 through June 1986 and with non-B acute lymphoblastic leukemia in the five Nordic countries. By January 1994, 315 children had suffered at least one relapse. The bone marrow was involved in 216 cases. There were 69 isolated CNS relapses, 25 isolated testicular recurrences and five relapses in other extramedullary sites. Of the 315 children with relapse, 94 are still in a second complete remission 12-138 (median: 78) months after relapse. The overall probability of a second event free survival (P-2.EFS) and survival after relapse was 0.28 and 0.33 respectively. The probability of remaining in second remission at 11 years was significantly correlated to the duration of first remission (P < 0.001), the site of relapse (P < 0.001) and gender (P = 0.004). The P-2.EFS for early, intermediate, and late bone marrow involved relapses were 0.08, 0.19, and 0.50 respectively. For early, intermediate and late isolated CNS relapses the P-2.EFS were 0.21, 0.38 and 0.61, respectively. The P-2.EFS for boys with isolated testicular relapses was 0.69. Girls with isolated CNS relapse (P < 0.001) and with bone marrow involved relapse (P = 0.04) had a significantly better prognosis than boys. Children with initial high risk criteria, especially T-ALL and mediastinal mass who relapsed, had a very poor prognosis. Conclusion: In this population-based study, about 30% of children with ALL obtained a long second remission and possible cure. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:372 / 378
页数:7
相关论文
共 50 条
  • [21] Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study
    Nguyen, K.
    Devidas, M.
    Cheng, S-C
    La, M.
    Raetz, E. A.
    Carroll, W. L.
    Winick, N. J.
    Hunger, S. P.
    Gaynon, P. S.
    Loh, M. L.
    [J]. LEUKEMIA, 2008, 22 (12) : 2142 - 2150
  • [22] Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study
    K Nguyen
    M Devidas
    S-C Cheng
    M La
    E A Raetz
    W L Carroll
    N J Winick
    S P Hunger
    P S Gaynon
    M L Loh
    [J]. Leukemia, 2008, 22 : 2142 - 2150
  • [23] Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study (vol 34, pg 336, 2020)
    Thastrup, Maria
    Marquart, Hanne Vibeke
    Levinsen, Mette
    Grell, Kathrine
    Abrahamsson, Jonas
    Albertsen, Birgitte Klug
    Frandsen, Thomas Leth
    Harila-Saari, Arja
    Lahteenmaki, Paivi Maria
    Niinimaki, Riitta
    Pronk, Cornelis Jan
    Ulvmoen, Aina
    Vaitkeviciene, Goda
    Taskinen, Mervi
    Schmiegelow, Kjeld
    [J]. LEUKEMIA, 2020, 34 (10) : 2822 - 2822
  • [24] Time trends in the incidence of acute lymphoblastic leukemia among children 1976-2002:: A population-based Nordic study
    Svendsen, Anne Louise
    Feychting, Maria
    Klaeboe, Lars
    Langmark, Froydis
    Schuez, Joachim
    [J]. JOURNAL OF PEDIATRICS, 2007, 151 (05): : 548 - 550
  • [25] Determinants of Survival After First Relapse of Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Study
    Loh, M.
    Rheingold, S.
    Bhojwani, D.
    Ji, L.
    Xu, X.
    Devidas, M.
    Brown, P.
    Gore, L.
    Winick, N.
    Carroll, W.
    Raetz, E.
    Hunger, S.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 : S8 - S8
  • [26] Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study
    E. Hulegårdh
    H. Hägglund
    L. Ahlberg
    K. Karlsson
    H. Karbach
    A. Markuszewska
    I. Persson
    M. Åström
    H. Hallböök
    [J]. Medical Oncology, 2014, 31
  • [27] Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study
    Hulegardh, E.
    Hagglund, H.
    Ahlberg, L.
    Karlsson, K.
    Karbach, H.
    Markuszewska, A.
    Persson, I.
    Astrom, M.
    Hallbook, H.
    [J]. MEDICAL ONCOLOGY, 2014, 31 (08)
  • [28] REINDUCTION THERAPY IN 297 CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN 1ST BONE-MARROW RELAPSE - A PEDIATRIC-ONCOLOGY-GROUP STUDY
    BUCHANAN, GR
    RIVERA, GK
    BOYETT, JM
    CHAUVENET, AR
    CRIST, WM
    VIETTI, TJ
    [J]. BLOOD, 1988, 72 (04) : 1286 - 1292
  • [29] Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
    Fuster, Jose L.
    Molinos-Quintana, Agueda
    Fuentes, Carolina
    Fernandez, Jose M.
    Velasco, Pablo
    Pascual, Toni
    Rives, Susana
    Dapena, Jose L.
    Sisinni, Luisa
    Lopez-Godino, Oriana
    Palomo, Pilar
    Villa-Alcazar, Marta
    Bautista, Francisco
    Gonzalez-Vicent, Marta
    Lopez-Duarte, Monica
    Garcia-Morin, Marina
    Ramos-Elbal, Eduardo
    Ramirez, Manuel
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (05) : 764 - 771
  • [30] Outcome of Chinese children with craniopharyngioma: a 20-year population-based study by the Hong Kong Pediatric Hematology/Oncology Study Group
    Liu, Anthony Pak-Yin
    Tung, Joanna Yuet-Ling
    Ku, Dennis Tak-Loi
    Luk, Chung-Wing
    Ling, Alvin Siu-Cheung
    Kwong, Dora Lai-Wan
    Cheng, Kevin King-Fai
    Ho, Wilson Wai-Shing
    Shing, Matthew Ming-Kong
    Chan, Godfrey Chi-Fung
    [J]. CHILDS NERVOUS SYSTEM, 2020, 36 (03) : 497 - 505